InxMed Co., Ltd. announced that IN0018 had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration. This designation is based on the results of a Phase Ib/II clinical trial of IN10018 for platinum-resistant ovarian cancer, with the proposed indication for the treatment of platinum-resistant ovarian cancer in combination with PEG-liposomal doxorubicin….
ZOMWE MUNGACHITE PA NKHANIYI:
- This designation is based on the results of a Phase Ib/II clinical trial of IN10018 for platinum-resistant ovarian cancer, with the proposed indication for the treatment of platinum-resistant ovarian cancer in combination with PEG-liposomal doxorubicin….
- .
- announced that IN0018 had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration.